AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Single recombinant anti-RhD IgG prevents RhD immunization.
2004 AUG 4 - (NewsRx.com & NewsRx.net) -- A single recombinant anti-RhD IgG prevents RhD immunization.
"A single recombinant immunoglobulin G1 (IgG1) anti-RhD antibody (MonoRho) was compared with a currently used polyclonal anti-RhD product (Rhophylac) in a phase 1 study for safety, efficacy of Rhesus D (RhD)-positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive RBCs. Both the polyclonal product and recombinant anti-RhD effectively cleared RhD-positive RBCs after intravenous and intramuscular injection. The recombinant anti-RhD demonstrated a slower clearance rate compared with the polyclonal anti-RhD," investigators in Switzerland, Germany, and the Netherlands report.
"There was no dose response, and there was considerable variation among subjects who received the same dose of recombinant anti-RhD," said Sylvia Miescher at ZLB Bioplasma AG in Switzerland and collaborators in Switzerland, Germany, and the Netherlands. "Interestingly, RhD-positive RBC clearance rates were strongly associated with Fcgamma receptor IIA (FcgammaRIIA) and FcgammaIIA but not with FcgammaIIIB polymorphisms. Subjects homozygous for FcgammaRIIA-131H or FcgammaRIIIA-158V allotypes showed a ...
- Recombinant anti-MUC1 scFv has improved stability.
- Newspaper article from: Health & Medicine Week June 28, 2004 700+ words
2004 JUN 28 - (NewsRx.com & NewsRx.net) -- A recombinant version of an anti-MUC1 scFv has greatly improved stability and efficacy. According to recent research from the United States, "[a]nti-MUC1 single-chain Fv (scFv) fragments generated from the humanized antibody huHMFG1 had adequate
- Cells from patients with chronic lymphocytic leukemia and adult T-cell leukemia...
- Newspaper article from: Cancer Weekly Kreitman, Robert J. Chaudhary, Vijay K. FitzGerald, David J.P. Waldmann, Thomas A. Pastan, Ira August 10, 1992 700+ words
AUTHORS: Robert J. Kreitman( 1), Vijay K. Chaudhary( 2), David J.P. FitzGerald( 1), Thomas A. Waldmann( 3), and Ira Pastan( 1). (1)Laboratory of Molecular Biology, DCBDC, U.S. National Cancer Institute, U.S. National Institutes of Health, 9000 Rockville Pike, 37/4E16, Bethesda, Maryland 20892;
- Reports by J.E.M. Gilmour and co-researchers describe recent advances in...
- Newspaper article from: Blood Weekly September 18, 2008 700+ words
...this study was to determine the effect of expressing a recombinant anti-Kell immunoglobulin (Ig) M from two cell lines, CH0...of the presence or absence of J chain on expression of recombinant anti-Kell immunoglobulin M. Transfusion Medicine, 2008...
- CHMP again turns down application for natalizumab.
- Newspaper article from: BioWorld International November 21, 2007 700+ words
...The chief issue before the panel was whether Tysabri, a recombinant anti-alpha4 integrin monoclonal antibody, had an appropriate...The chief issue before the panel was whether Tysabri, a recombinant anti-alpha4 integrin monoclonal antibody, had an appropriate...
- Biovitrum and Symphogen Enter Co-Development and Commercialization Agreement...
- Press release article from: Business Wire February 1, 2006 700+ words
...lead product. Sym001 is a combination of 25 different recombinant anti-Rhesus D antibodies for the treatment of both Idiopathic...Symphogen's lead product, Sym001, combines 25 different recombinant anti-Rhesus D (RhD) antibodies for the treatment of Idiopathic...
- Infectious disease antibodies.(LITERATURE FOCUS)(Advertisement)
- Magazine article from: Bioscience Technology April 1, 2005 700+ words
ViroStat, Inc. is a primary manufacturer of infectious disease antibodies and recombinant anti-gens, including monoclonal and polyclonal antibodies to food-borne pathogens, respiratory viruses, STD agents, hepatitis...
- Genzyme to Establish Research Facility in Europe; Cambridge, England Chosen for...
- Press release article from: PR Newswire January 14, 2004 700+ words
...comprehensive and growing. These include a marketed product-Thymoglobulin(R) (anti-thymocite globulin) -- and two recombinant anti-TGF beta antibodies -- one in clinical trials for scleroderma and one about to enter trials for idiopathic pulmonary...
- Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First...
- Press release article from: Business Wire March 12, 2007 700+ words
...and anti-RhD prophylaxis of Hemolytic Disease of the Newborn (HDN). The product, Sym001, consists of 25 different recombinant anti-Rhesus D antibodies. COPENHAGEN, Denmark & STOCKHOLM, Sweden -- Symphogen and Biovitrum today announced the...
- Anti-idiotypic antibody fragment effective against candidiasis.
- Newspaper article from: Vaccine Weekly January 7, 2004 700+ words
...effective against experimental mucosal and systemic candidiasis. "Peptides derived from the sequence of a single-chain, recombinant, anti-idiotypic antibody (IdAb; KT-scFv) acting as a functional internal image of a microbicidal, wide-spectrum yeast...
- The role of antitissue transglutaminase assay for the diagnosis and monitoring...
- Magazine article from: Journal of Clinical Pathology Tonutti, E. Visentini, D. Bizzaro, N. Caradonna, M. Cerni, L. Villalta, D. Tozzoli, R. May 1, 2003 700+ words
...showed that of the 162 sera classified as EMA negative/antiguinea pig tTG positive, only 49 were positive for human recombinant anti-tTG, and that 39 of these were also EMA positive. Furthermore, of the 36 sera classified as EMA positive/antiguinea...
Source: HighBeam Research, Single recombinant anti-RhD IgG prevents RhD immunization.